
<html>

<head>
<meta name="GENERATOR" content="Microsoft FrontPage 3.0">
<title>Pleiotropic Effects of Statins in Atherosclerosis and Diabetes</title>
</head>

<body bgcolor="#FFFFFF">
<div align="left">

<table border="1" cellpadding="2" width="25" bordercolor="#74656A" bordercolorlight="#74656A" bordercolordark="#74656A">
  <tr>
    <td><font size="5"><b>Diabetes</b></font></td>
    <td bgcolor="#FFFFFF"><font color="#74656A" size="5"><b>Care </b></font></td>
  </tr>
</table>
</div>

<p><font color="#74656A"><strong>Volume&nbsp;23 Supplement 2 <br>
Data, Results, and Consequences of Major Trials With Focus on Type 2 Diabetes<br>
Proceedings from a Symposium</strong></font></p>
<div align="left">

<table border="0" cellpadding="5" cellspacing="3" width="600">
  <tr>
    <td><div CLASS="s0"><hr>
    <font COLOR="#FFFFFF" SIZE="2"><p></font><strong><font color="#000000" size="3">ORIGINAL
    ARTICLE</font></strong></p>
    <hr>
    <p><strong><font SIZE="6">Pleiotropic Effects of Statins in Atherosclerosis and Diabetes</font></strong></p>
    <hr>
    </div><div CLASS="Authors"><font SIZE="2"><p></font><font face="Times New Roman" size="3">Stefano
    Bellosta, PHD<br>
    Nicola Ferri, PHD<br>
    Lorenzo Arnaboldi, PHD<br>
    Franco Bernini, PHD<br>
    Rodolfo Paoletti, MD<br>
    Alberto Corsini, PHD</font></p>
    </div><div CLASS="Reprint-first"><hr>
    </div><div CLASS="Abstract"><p><font face="Times New Roman" size="3"><strong>OBJECTIVE</strong>
    &#151; To investigate the direct anti-atherosclerotic properties of statins.</font></p>
    </div><div CLASS="Abstract"><p><font face="Times New Roman" size="3"><strong>RESEARCH
    DESIGN AND METHODS</strong> &#151; Using in vitro and ex vivo models, the effect of
    different statins on key events involved in atherogenesis has been investigated. We
    studied the ability of statins to modulate modified LDL-induced cholesterol
    esterification, metalloproteinase secretion by macrophages, and arterial myocyte migration
    and proliferation. The mechanisms underlying the inhibitory effect of statins have also
    been explored. Finally, the antiproliferative effect of sera from statin-treated patients
    has been confirmed in a cell culture system.</font></p>
    </div><div CLASS="Abstract"><p><font face="Times New Roman" size="3"><strong>RESULTS</strong>
    &#151; Fluvastatin, simvastatin, lovastatin, atorvastatin, and cerivastatin, but not
    pravastatin, dose-dependently decrease smooth muscle cell (SMC) migration and
    proliferation. Moreover, statins are able to reduce cholesterol accumulation in
    macrophages in vitro by blocking cholesterol esterification and endocytosis of modified
    lipoproteins and matrix-degrading enzyme secretion. This in vitro inhibition was
    completely prevented by mevalonate and partially by all-<i>trans</i> farnesol and all-<i>trans</i>
    geranylgeraniol, confirming the specific role of isoprenoid metabolites (probably through
    prenylated protein[s]) in regulating these cellular events. The inhibitory effect of
    statins on SMC proliferation has been shown in different models of proliferating cells,
    such as cultured arterial myocytes and rapidly proliferating carotid and femoral intimal
    lesions in rabbits, independently of their ability to reduce plasma cholesterol. Finally,
    ex vivo studies showed that sera from fluvastatin-treated patients interfere with SMC
    proliferation.</font></p>
    </div><div CLASS="Abstract"><p align="left"><font face="Times New Roman" size="3"><strong>CONCLUSIONS</strong>
    &#151; These results suggest that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
    reductase inhibitors exert a direct anti-atherosclerotic effect in the arterial wall,
    beyond their effects on plasma lipids that could translate into a more significant
    prevention of cardiovascular disease. These findings provide a basis for the beneficial
    effect of statins in clinical trials also involving diabetic patients&#151;a population
    with a higher absolute risk of recurrent cardiovascular events.</font></p>
    <p align="right"><font face="Times New Roman" size="3"><i>Diabetes Care</i> 23 (Suppl.
    2):B72&#150;B78, 2000</font></p>
    </div><div CLASS="tagline"><hr>
    <p><strong><font face="Times New Roman" size="5">I</font></strong><font CLASS="s8" face="Times New Roman" size="3">t is well known that the risk of coronary heart disease
    (CHD) death and serious nonfatal CHD events is markedly elevated in diabetic patients (<a href="#1">1</a>,<a href="#2">2</a>). Furthermore, clinically manifest CHD has a worse
    prognosis in diabetic patients than in normal subjects (<a href="#3">3</a>&#150;<a href="#5">5</a>). The adverse effects of diabetes on serum lipids and other general
    cardiovascular risk factors could explain the excessive CHD risk in diabetic patients, but
    a large</font><font face="Times New Roman" size="3">part of this risk is evidently caused
    by enhancing effects of the diabetic state itself on atherogenesis and/or thrombogenesis (<a href="#6">6</a>).</font></p>
    </div><div CLASS="BodyText"><p><font face="Times New Roman" size="3">Clinical and
    experimental studies have firmly shown that reduction of plasma cholesterol, particularly
    LDL cholesterol, lowers the risk of cardiovascular events in both primary and secondary
    prevention trials. The more recent cholesterol-lowering drugs, the
    3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors (statins), can achieve a
    relatively large reduction of plasma cholesterol. Clinical trials have demonstrated that
    statins can induce regression of vascular atherosclerosis as well as reduction of
    cardiovascular-related morbidity and mortality in patients with and without coronary
    artery disease (Scandinavian Simvastatin Survival Study [4S], West of Scotland Coronary
    Prevention Study, Cholesterol and Recurrent Events [CARE], Long-Term Intervention with
    Pravastatin in Ischemic Disease [LIPID] Study, and Air Force/Texas Coronary
    Atheriosclerosis Prevention Study (<a href="#7">7</a>&#150;<a href="#11">11</a>).
    Moreover, a post hoc subgroup analysis of the data on diabetic patients included in the 4S
    Study provided the first trial-based evidence that cholesterol lowering with simvastatin
    improves the prognosis of diabetic patients with CHD (<a href="#12">12</a>).</font></p>
    </div><div CLASS="BodyText"><p><font face="Times New Roman" size="3">It is usually assumed
    that any beneficial effect of statins on coronary events is linked to their
    hypocholesterolemic properties. However, because mevalonic acid (MVA), intracellularly
    synthesized by HMG-CoA reductase, is the precursor of numerous metabolites, inhibition of
    HMG-CoA reductase has the potential to result in pleiotropic effects (<a href="#13">13</a>&#150;<a href="#16">16</a>); hence, effects other than cholesterol reduction may help to explain
    the anti-atherosclerotic properties of statins. Key events in the atherogenic cascade are
    the migration and proliferation of arterial myocytes and the deposition of lipids, mainly
    cholesteryl esters, in the arterial wall (<a href="#17">17</a>&#150;<a href="#19">19</a>).
    MVA and other intermediates of cholesterol biosynthesis (isoprenoids) are essential for
    these processes (<a href="#15">15</a>,<a href="#16">16</a>,<a href="#20">20</a>); hence,
    it is conceivable that statins can directly affect major events occurring in the arterial
    wall during atherogenesis.</font></p>
    </div><div CLASS="BodyText"><p><font face="Times New Roman" size="3">In the present
    article, we summarize our experience in investigating the direct anti-atherosclerotic
    properties of statins and discuss their potential beneficial effects in diabetic patients.</font></p>
    </div><div CLASS="H1"><p><strong><font face="Times New Roman" size="3">RESEARCH DESIGN AND
    METHODS</font></strong></p>
    </div><div CLASS="H1"><p><font face="Times New Roman" size="3"><strong>Cell cultures</strong><br>
    Mouse peritoneal macrophages were obtained from mice (BALB/C; Charles River, Calco, Italy)
    after intraperitoneal injection of thioglycollate. Cells (3 </font><font fontsize="10" face="Arial" size="2">X</font><font face="Times New Roman" size="3"> 10<sup>6</sup> per
    35-mm dish) were plated in Dulbecco's minimum essential medium (MEM) containing 10% fetal
    calf serum. After 2 h, dishes were washed to eliminate unattached cells and maintained in
    Dulbecco's MEM plus fetal calf serum until required.</font></p>
    </div><div CLASS="BodyText"><p><font face="Times New Roman" size="3">Smooth muscle cells
    (SMCs) were cultured according to Ross (<a href="#21">21</a>) from the intima-media layers
    of the aortas of male Sprague-Dawley rats (weighing 200&#150;250 g), as previously
    described (<a href="#16">16</a>). Human vascular myocytes (A617 from femoral artery) were
    grown as described (<a href="#16">16</a>).</font></p>
    </div><div CLASS="H1"><p><font face="Times New Roman" size="3"><strong>Cholesterol
    esterification</strong><br>
    To determine cholesterol esterification, murine macrophages were incubated for 24 h in the
    absence or presence of acetylated LDL (50 �g/ml) and for a further 24 h with the
    indicated concentration of drugs. Cells were subsequently incubated for 24 h in the same
    fresh media also containing acetylated LDL (5 �g/ml). During the last 2 h of incubation <sup>14</sup>C-oleic
    acid was added, and cholesteryl <sup>14</sup>C-oleate formation was measured by
    scintillation counting.</font></p>
    </div><div CLASS="H1"><p><font face="Times New Roman" size="3"><strong>Activity and
    secretion of gelatinase B by human macrophages</strong><br>
    Human macrophages were incubated for 24 h with medium alone (control) or containing the
    indicated concentrations of fluvastatin. Conditioned media were collected, and the amount
    of secreted metalloproteinase (MMP)-9 was measured by using a highly specific Biotrak
    Matrix Metalloproteinase-9 ELISA system (Amersham, U.K.), as suggested by the
    manufacturer. MMP-9 activity was assessed by gelatin zymography (<a href="#22">22</a>).</font></p>
    </div><div CLASS="H1"><p><font face="Times New Roman" size="3"><strong>Migration of SMCs</strong><br>
    Migration of SMCs was examined using a 48-well microchemotaxis chamber. Freshly
    tripsinized SMCs were suspended in Eagle's MEM supplemented with 5% serum. The lower
    wells, containing 27 �l of medium including fibrinogen (600 �g/ml) as the chemotactic
    factor, were covered with a polyvinylpyrrolidone-free polycarbonate filter (8-�m pore
    size). There was 50 �l of the cell suspension (10<sup>6</sup> cells/ml) placed in the
    upper compartment with the tested drugs and incubated for 5 h at 37�C. Migrated cells
    were stained with Diff-Quik and counted under a high power field (100</font><font fontsize="10" face="Arial" size="2">X</font><font face="Times New Roman" size="3">).
    Values are the mean � SD of triplicate dishes. Six high power fields were counted per
    sample and the results averaged.</font></p>
    </div><div CLASS="H1"><p><font face="Times New Roman" size="3"><strong>SMC proliferation</strong><br>
    Myocytes were seeded at a density of 5 </font><font fontsize="10" face="Arial" size="2">X</font><font face="Times New Roman" size="3"> 10<sup>4</sup> per 35-mm dish (human) or 2 </font><font fontsize="10" face="Arial" size="2">X</font><font face="Times New Roman" size="3"> &nbsp;
    10<sup>5</sup> per 35-mm dish (rat) and incubated with MEM supplemented with 10% fetal
    calf serum; 24 h later, the medium was replaced with one containing 0.4% fetal calf serum
    to stop cell growth, and the cultures were incubated for 72 h. At this time (time 0), the
    medium was replaced with one containing 10% fetal calf serum plus the compounds under
    investigation. All tested compounds were in the active hydroxy acid form. The incubation
    was continued for a further 72 h at 37�C. After trypsinization of SMC monolayers,
    proliferation was evaluated by counting cell numbers using a Coulter Counter (model ZM;
    Coulter Instruments, Milan, Italy) (<a href="#14">14</a>,<a href="#18">18</a>). The
    concentrations of drugs required to inhibit 50% of cell proliferation (IC<sub>50</sub>)
    were computed by linear regression analysis of the logarithm of the concentrations
    (�mol/l) versus probits, and the value was obtained from a probit transformation.</font></p>
    </div><div CLASS="H1"><p><font face="Times New Roman" size="3"><strong>Synthesis of total
    sterols</strong><br>
    Cholesterol biosynthesis was determined in the same experimental conditions as previously
    described (<a href="#16">16</a>), measuring the incorporation of <sup>14</sup>C-acetate
    into total cellular sterols.</font></p>
    <div align="center"><center><table border="1" cellpadding="2">
      <tr>
        <td width="100%"><img src="tables/bellostaT1.jpg" alt="bellostaT1.jpg (20841 bytes)" WIDTH="493" HEIGHT="218"></td>
      </tr>
    </table>
    </center></div></div><div CLASS="H1"><p><strong><font face="Times New Roman" size="3">RESULTS</font></strong></p>
    </div><div CLASS="H1"><p><font face="Times New Roman" size="3"><strong>In vitro studies:
    effects on cultured cells</strong><br>
    <strong>Studies in macrophages.</strong> Studies performed in primary culture of mouse
    peritoneal macrophages showed that fluvastatin and simvastatin, but not pravastatin,
    dose-dependently inhibited the esterification of cellular cholesterol induced by
    acetylated LDL (<a href="#15">15</a>) (Table 1). This inhibition causes a
    concentration-dependent decrease of the cellular content of esterified cholesterol by
    &gt;70% (data not shown). The addition of mevalonate or all-<i>trans </i>geranylgeraniol
    (GG-OH) fully prevented the inhibitory effect of fluvastatin (Table 2), suggesting that a
    mevalonate nonsterol derivative(s) is involved in the esterification of exogenous
    cholesterol delivered to macrophages by modified LDL (<a href="#15">15</a>).
    Interestingly, data reported in Table 3 show that the efficacy of fluvastatin in
    inhibiting cholesterol esterification was greater in cholesterol-loaded cells than in
    normal cells, suggesting a possible specific and more pronounced effect in foam cells.
    These results may be explained by considering that in cholesterol-rich cells, HMG-CoA
    reductase activity is already largely reduced compared with unloaded cells (<a href="#23">23</a>).</font></p>
    <div align="center"><center><table border="1" cellpadding="2">
      <tr>
        <td width="100%"><img src="tables/bellostaT2.jpg" alt="bellostaT2.jpg (22045 bytes)" WIDTH="493" HEIGHT="187"></td>
      </tr>
    </table>
    </center></div></div><div CLASS="BodyText"><div align="center"><center><table border="0" cellpadding="2">
      <tr>
        <td width="100%"></td>
      </tr>
    </table>
    </center></div><div align="center"><center><table border="1" cellpadding="2">
      <tr>
        <td><img src="tables/bellostaT3.jpg" alt="bellostaT3.jpg (21678 bytes)" WIDTH="493" HEIGHT="216"></td>
      </tr>
    </table>
    </center></div><p><font face="Times New Roman" size="3">In addition to their effects on
    lipid accumulation in macrophages, statins (namely fluvastatin and simvastatin) were able
    to inhibit MMP-9 (gelatinase B) gelatinolytic activity and secretion by human macrophages
    in culture (an effect prevented by the coincubation with MVA [Table 4] [<a href="#22">22</a>]),
    providing further insights on their direct anti-atherosclerotic potentials.</font></p>
    <div align="center"><center><table border="1" cellpadding="2">
      <tr>
        <td width="100%"><img src="tables/bellostaT4.jpg" alt="bellostaT4.jpg (20272 bytes)" WIDTH="493" HEIGHT="174"></td>
      </tr>
    </table>
    </center></div></div><div CLASS="H3"><p><font face="Times New Roman" size="3"><strong>Studies
    in arterial myocytes.</strong> The effects of different statins on the proliferation of
    rat aorta and human femoral arterial myocytes have been studied. All statins, except
    pravastatin, decreased the replication of human and rat aorta myocytes (<a href="#16">16</a>,<a href="#24">24</a>) (Table 5). The ability of MVA, all-<i>trans</i> farnesol (F-OH), or all<i>-trans</i>
    GG-OH to prevent the inhibitory effect of statins on SMC proliferation (Table 6) indicates
    that the effect elicited by this class of drugs is related to the inhibition of the MVA
    pathway (<a href="#20">20</a>,<a href="#24">24</a>,<a href="#25">25</a>).</font></p>
    <div align="center"><center><table border="1" cellpadding="2">
      <tr>
        <td width="100%"><img src="tables/bellostaT5.jpg" alt="bellostaT5.jpg (27196 bytes)" WIDTH="238" HEIGHT="392"></td>
      </tr>
    </table>
    </center></div></div><div CLASS="BodyText"><p><font face="Times New Roman" size="3">The
    failure of pravastatin to inhibit the replication of vascular myocytes may be related to
    the hydrophilicity of the drug, which impairs diffusion through the plasma membrane of
    extrahepatic cells and limits its capacity to inhibit cholesterol biosynthesis (<a href="#26">26</a>). On the other hand, pravastatin is internalized via an active transport
    mechanism into hepatocytes, thus explaining its ability to inhibit cholesterol synthesis
    to a degree comparable to other statins in these cells, achieving a good
    hypocholesterolemic effect (<a href="#27">27</a>).</font></p>
    </div><div CLASS="BodyText"><p><font face="Times New Roman" size="3">The effect of statins
    on migration of rat aortic myocytes incubated for 5 h, in the presence of fibrinogen as a
    chemotactic factor, was also investigated. Fluvastatin, simvastatin, and cerivastatin, but
    not pravastatin, dose-dependently inhibited the fibrinogen-induced migration of arterial
    myocytes (Fig. 1) (<a href="#20">20</a>,<a href="#24">24</a>). The fact that MVA, all-<i>trans</i>
    F-OH, or all-<i>trans </i>GG-OH prevented the inhibitory effect of statins (<a href="#20">20</a>,<a href="#24">24</a>) suggests that isoprenoid metabolites also play a specific role in
    regulating cell migration.</font></p>
    <div align="center"><center><table border="1" cellpadding="2" width="480">
      <tr>
        <td width="100%"><img src="images/010651a.gif" alt="010651a.gif (55845 bytes)" WIDTH="480" HEIGHT="446"></td>
      </tr>
      <tr>
        <td width="100%"><font face="Times New Roman" size="3"><strong>Figure</strong> <strong>1</strong>&#151;</font><font color="#000000" face="Times New Roman" size="3"><i>Effect of HMG-CoA reductase inhibitors
        on the fibrinogen-induced migration of rat aortic myocytes. Drug versus control: *</i>P
        &lt;<i> 0.05; **</i>P &lt;<i> 0.01 (Student's</i> t <i>test). </i><img src="symbollibrary/squareopen.gif" align="absbottom" WIDTH="15" HEIGHT="19"><i>, Control; </i></font><img src="SymbolLibrary/squaremorelines.gif" alt="squaremorelines.gif (276 bytes)" align="absbottom" WIDTH="15" HEIGHT="19"><font color="#000000"><font size="3"><font face="Times New Roman"> </font></font><i><font face="Times New Roman" size="3">fluvastatin; <img src="SymbolLibrary/SqCriscros.gif" alt="SqCriscros.gif (964 bytes)" align="absbottom" WIDTH="15" HEIGHT="19">, simvastatin; <img src="SymbolLibrary/squarebiglines.gif" alt="squarebiglines.gif (1027 bytes)" align="absbottom" WIDTH="15" HEIGHT="19">, cerivastatin; <img src="SymbolLibrary/Squareplus.gif" alt="Squareplus.gif (947 bytes)" align="absbottom" WIDTH="15" HEIGHT="19">, pravastatin.</font></i></font></td>
      </tr>
    </table>
    </center></div></div><div CLASS="H1"><p><font face="Times New Roman" size="3"><strong>Ex
    vivo studies</strong><br>
    <strong>Studies with sera from statin-treated patients.</strong> Because fluvastatin
    inhibits SMC proliferation at therapeutic concentrations (0.1&#150;1 �mol/l) (<a href="#28">28</a>,<a href="#29">29</a>), we investigated the pharmacological activity of
    sera from patients treated with fluvastatin as compared with the more hydrophilic
    pravastatin, which displays a lipid-lowering effect similar to fluvastatin but no in vitro
    effects on SMC proliferation. Fluvastatin (40 mg once a day) and pravastatin (40 mg once a
    day), given for 6 days to patients with type IIa hypercholesterolemia, resulted in a
    similar decrease of LDL cholesterol levels. However, cholesterol biosynthesis and cell
    proliferation in cultured human SMCs exposed to 15% sera from patients treated with either
    pravastatin or fluvastatin showed striking differences (<a href="#30">30</a>).
    Pravastatin-treated samples essentially did not cause any changes either in cholesterol
    biosynthesis or SMC proliferation. In contrast, the treatment of cells with sera drawn
    from fluvastatin-treated patients 6 h after the last dose resulted in a 43% inhibition of
    cholesterol biosynthesis in SMCs and in a progressive reduction of cell proliferation (<u>&lt;</u>30%)
    (<a href="#30">30</a>).</font></p>
    <div align="center"><center><table border="1" cellpadding="2">
      <tr>
        <td width="100%"><img src="tables/bellostaT6.jpg" alt="bellostaT6.jpg (31441 bytes)" WIDTH="493" HEIGHT="277"></td>
      </tr>
    </table>
    </center></div></div><div CLASS="H1"><p><font face="Times New Roman" size="3"><strong>CONCLUSIONS</strong>
    &#151; Our results clearly demonstrate the ability of statins to modulate key events
    involved in atherogenesis, independently of their lipid-lowering properties. These
    anti-atherosclerotic effects of statins result from the inhibition of HMG-CoA reductase
    activity, e.g., their primary action. In particular, we have shown that lipophilic statins
    are able to inhibit cholesterol accumulation and to reduce the secretion of MMP-9 (<a href="#22">22</a>). Until recently, it was thought that the major pathophysiological
    mechanism by which atherosclerosis contributes to various coronary syndromes was a slowly
    progressive luminal obstruction by atherosclerotic plaque that eventually resulted in
    decreased coronary blood flow reserve and subsequent myocardial ischemia. However, it is
    now becoming clearer that the &quot;stability&quot; of the plaque is one important aspect
    that has to be taken into account. Plaque disruption with superimposed thrombosis is the
    main cause for the acute coronary syndrome of unstable angina, myocardial infarction, and
    sudden death (<a href="#31">31</a>). Plaque instability, manifesting as ulceration of the
    fibrous cap, plaque rupture, and intraplaque hemorrhage, is characteristic of plaques with
    a high content of lipid and an excess of macrophages in the cap (<a href="#32">32</a>,<a href="#33">33</a>). Macrophages are capable of degrading the extracellular matrix by
    phagocytosis or by secreting proteolytic enzymes&#151;in particular, a family of
    metalloproteinases (MMPs) that may weaken the fibrous cap, predisposing its rupture (<a href="#34">34</a>). The inhibitory effect of statins on MMP-9 secretion observed in our
    study (<a href="#22">22</a>) suggests a potential stabilizing effect of these drugs on the
    atherosclerotic plaque.</font></p>
    </div><div CLASS="BodyText"><p><font face="Times New Roman" size="3">We have also shown,
    by using in vitro and ex vivo models, the ability of statins to interfere with migration
    and proliferation of arterial myocytes. Our results indicate that conditions producing a
    complete inhibition of cholesterol biosynthesis correlate with ~50% inhibition of cell
    growth (<a href="#35">35</a>). The ability of mevalonate or its isoprenoid derivatives,
    F-OH and GG-OH, to restore SMC proliferation indicates that the effect elicited by statins
    is related to the inhibition of the mevalonate pathway. Recently, several proteins
    involved in growth factor signal transduction have been shown to be lipid-modified by the
    covalent attachment of mevalonate-derived isoprenoid groups. Statins inhibit cell
    proliferation by reducing the biosynthesis of these isoprenoids (<a href="#35">35</a>).</font></p>
    </div><div CLASS="BodyText"><p><font face="Times New Roman" size="3">The ability of
    fluvastatin to interfere with arterial SMC proliferation at therapeutic concentrations
    (0.1&#150;1 �mol/l) prompted us to investigate the pharmacological activity of sera from
    patients treated with fluvastatin on the proliferation of cultured human arterial myocytes
    (<a href="#30">30</a>,<a href="#36">36</a>). Addition of whole-blood sera to the culture
    medium resulted in an inhibition of cholesterol synthesis as well as of SMC proliferation
    that mirrored the pharmacokinetic profile of fluvastatin. The antiproliferative activity
    of sera from fluvastatin-treated patients is the first demonstration in humans (<a href="#30">30</a>) and may provide a basis for the potential effect of fluvastatin in the
    Fluvastatin Angioplasty Restenosis clinical trial on the prevention of coronary restenosis
    after angioplasty (<a href="#37">37</a>). Although the results of the study clearly showed
    no benefits of fluvastatin treatment on the process of restenosis, in agreement with
    previous published restenosis trails using statins (<a href="#38">38</a>,<a href="#39">39</a>),
    a significant reduction in mortality and myocardial infarction has been observed after 40
    weeks of treatment with the statin. This clinical benefit could be explained by the rapid
    reduction of LDL cholesterol levels and by potential anti-atherothrombotic properties of
    fluvastatin (<a href="#37">37</a>).</font></p>
    </div><div CLASS="BodyText"><p><font face="Times New Roman" size="3">The inhibitory
    effects of statins on SMCs and macrophages might provide examples for a general
    pharmacodynamic mechanism of this class of drugs, in which effectiveness has been shown in
    different models of atherosclerosis (<a href="#40">40</a>). It has indeed been reported
    that statins display other anti-atherogenic effects possibly related to their primary
    action on HMG-CoA reductase. These effects include the ability of statins to modulate
    tissue factor activity and expression in human macrophages (<a href="#41">41</a>) as well
    as fibrinolytic activity (<a href="#42">42</a>), oxidation of lipoproteins (<a href="#43">43</a>)
    and macrophage growth induced by oxidized LDL (<a href="#44">44</a>), superoxide
    generation (<a href="#45">45</a>), natural killer T-cell function (<a href="#46">46</a>),
    scavenger receptor expression (<a href="#47">47</a>), lipoprotein secretion (<a href="#48">48</a>),
    cell adhesion (<a href="#49">49</a>), endothelial nitric oxide synthase (<a href="#50">50</a>),
    and endothelin-1 synthesis and expression (<a href="#51">51</a>).</font></p>
    </div><div CLASS="BodyText"><p><font face="Times New Roman" size="3">These in vitro
    findings have been corroborated in rabbit models of atherogenesis, which demonstrated the
    ability of a variety of statins to reduce the extent of carotid and femoral intimal
    lesions induced by vascular injury (<a href="#52">52</a>&#150;<a href="#55">55</a>). In
    these in vivo models, the effect of statins was not associated with significant changes in
    serum cholesterol concentrations (<a href="#52">52</a>&#150;<a href="#58">58</a>). Other
    in vivo models (monkeys, mice), as well as models in humans, demonstrate that statin
    therapy can stabilize atherosclerotic plaques and improve endothelial function in the
    absence of significant changes in serum cholesterol levels (<a href="#50">50</a>,<a href="#59">59</a>,<a href="#60">60</a>).</font></p>
    </div><div CLASS="BodyText"><p><font face="Times New Roman" size="3">Numerous mechanisms,
    therefore, may contribute to the beneficial anti-atherosclerotic effect of HMG-CoA
    reductase inhibitors, and the results of several of the most recent clinical trials may,
    indeed, extend beyond cholesterol reduction. Lipid-lowering clinical trials suggest that
    despite comparable reduction in serum cholesterol levels, the risk of cardiovascular
    events in statin-treated patients is lower compared with other agents or modalities used
    to decrease serum cholesterol levels (<a href="#61">61</a>).</font></p>
    </div><div CLASS="BodyText"><p><font face="Times New Roman" size="3">The
    non&#150;lipid-related properties of statins may help to explain the early and significant
    cardiovascular event reduction reported in several clinical trials (<a href="#7">7</a>,<a href="#8">8</a>,<a href="#10">10</a>,<a href="#11">11</a>). Additional support for this
    hypothesis is provided by the Lipoprotein and Coronary Atherosclerosis Study (<a href="#62">62</a>), which investigated the progression and regression of atherosclerotic
    lesions after fluvastatin treatment. The results of this angiographic trial show that
    fluvastatin reduces the progression of atherosclerotic lesions as well as cardiovascular
    clinical end points. The beneficial effect was consistent across all baseline LDL
    cholesterol subgroups from normal to moderately hypercholesterolemic patients.</font></p>
    </div><div CLASS="BodyText"><p><font face="Times New Roman" size="3">Altogether, clinical
    and experimental evidence has established that statins, beyond their lipid-lowering
    properties, exert a direct anti-atherosclerotic effect in the arterial wall that could
    translate into a more significant prevention of cardiovascular disease in high-risk
    populations. The question whether statin treatment is also beneficial in diabetes still
    remains to be answered.</font></p>
    </div><div CLASS="BodyText"><p><font face="Times New Roman" size="3">Several potential
    mechanisms could contribute to the development of an early atherosclerotic lesion in
    diabetic patients. Among them, the role of abnormal lipoproteins, a procoagulant state,
    insulin resistance and hyperinsulinemia, glycation of proteins in plasma and the arterial
    wall, glycoxidation, growth factors, and enhanced SMC proliferation and foam cell
    formation are well established (<a href="#63">63</a>). The pleiotropic properties of
    statins could represent a potential mean for controlling the multifactorial
    atherosclerosis present in diabetic individuals. However, only a few experimental studies
    regarding the effect of statins on serum lipid level in diabetic animals have been
    published (<a href="#64">64</a>,<a href="#65">65</a>). In addition, clinical trials
    addressing the effects of statins in diabetic patients are limited to post hoc analysis of
    investigations aimed primarily at decreasing LDL cholesterol levels rather than analyzing
    diabetes complications as a primary end point.</font></p>
    </div><div CLASS="BodyText"><p><font face="Times New Roman" size="3">The 4S Study has
    provided the first trial-based evidence showing that cholesterol lowering reduces the risk
    of major CHD events and other atherosclerotic events in diabetic patients with CHD (<a href="#7">7</a>). Among the 4,444 patients with previous myocardial infarction or angina
    pectoris enrolled in the study, 202 diabetic patients were assigned to placebo or
    simvastatin. Over the 5.4-year median follow-up period, simvastatin treatment produced
    similar changes in serum lipids in diabetic individuals as compared with the other CHD
    patients. However, because of the higher absolute risk of recurrent CHD events in diabetic
    patients, the absolute clinical benefit achieved by cholesterol lowering in terms of
    events prevented was greater in diabetic patients with CHD than in nondiabetic patients
    with CHD (<a href="#7">7</a>).</font></p>
    </div><div CLASS="BodyText"><p><font face="Times New Roman" size="3">It is noteworthy that
    two other secondary prevention trials investigating the effect of pravastatin on coronary
    events did not confirm the greater benefit in the diabetic population (<a href="#9">9</a>,<a href="#10">10</a>). In fact, in both studies, a similar reduction in coronary events has
    been observed in diabetic and nondiabetic patients. The reason for this lack of an
    additional benefit could be due to the lower baseline total cholesterol level in the CARE
    and LIPID trials (<a href="#9">9</a>,<a href="#10">10</a>), as compared to the 4S trial (<a href="#7">7</a>). On the other hand, the hydrophilicity of pravastatin could hamper its
    diffusion into the arterial wall (<a href="#26">26</a>), thus blunting its direct
    anti-atherosclerotic properties. Finally, two primary prevention trials with statins
    enrolled too few diabetic patients, thus precluding any relevant analysis in this
    population (<a href="#8">8</a>,<a href="#11">11</a>).</font></p>
    </div><div CLASS="BodyText"><p><font face="Times New Roman" size="3">All things
    considered, we cannot draw any definitive conclusions on the additional clinical benefit
    of statin therapy in diabetic patients, since LDL cholesterol is not consistently elevated
    in type 2 diabetes, where the main abnormalities are elevated triglycerides and low HDL (<a href="#63">63</a>). Trials investigating the effect of statins in type IV or type IIb
    hyperlipidemic diabetic patients are required to exhaustively address the pleiotropic
    properties of statins beyond LDL cholesterol lowering.</font></p>
    <hr>
    </div><div CLASS="RefsHead"><p><strong><font face="Times New Roman" size="3">References</font></strong></p>
    <p><font face="Times New Roman" size="3"><a name="1">1.</a> Kannel WB, McGee DL: Diabetes
    and cardiovascular disease: the Framingham Study. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=430798&amp;form=6&amp;db=m&amp;Dopt=b"><i>JAMA</i>
    241:2035&#150;2038, 1979</a></font></p>
    </div><div><a name="2"><p><font face="Times New Roman" size="3">2.</a> Fuller JH, Shipley
    MJ, Rose G, Jarrett RJ, Keen H: Coronary-heart-disease risk and impaired glucose
    tolerance: the Whitehall Study. <i>Lancet</i> i:1373&#150;1376, 1980</font></p>
    </div><div><a name="3"><p><font face="Times New Roman" size="3">3.</a> Smith JW, Marcus
    FI, Serokman R: The Multicenter Postinfarction Research Group: prognosis of patients with
    diabetes mellitus after myocardial infarction. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6385680&amp;form=6&amp;db=m&amp;Dopt=b"><i>Am
    J Cardiol</i> 54:718&#150;721, 1984</a></font></p>
    </div><div><a name="4"><p><font face="Times New Roman" size="3">4.</a> Abbot RD, Donahue
    RP, Kannel WB, Wilson PW: The impact of diabetes on survival following myocardial
    infarction in men vs women: the Framingham Study. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2974889&amp;form=6&amp;db=m&amp;Dopt=b"><i>JAMA</i>
    260:3456&#150;3460, 1988</a></font></p>
    </div><div><a name="5"><p><font face="Times New Roman" size="3">5.</a> Malmberg K, Ryden
    L: Myocardial infarction in patients with diabetes. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3383866&amp;form=6&amp;db=m&amp;Dopt=b"><i>Eur
    Heart J</i> 9:259&#150;264, 1988</a></font></p>
    </div><div><a name="6"><p><font face="Times New Roman" size="3">6.</a> Pyorala K, Laakso
    M, Uusitupa M: Diabetes and atherosclerosis: an epidemiologic view. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3552530&amp;form=6&amp;db=m&amp;Dopt=b"><i>Diabetes
    Metab Rev</i> 3:463&#150;524, 1987</a></font></p>
    </div><div><a name="7"><p><font face="Times New Roman" size="3">7.</a> Scandinavian
    Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444
    patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7968073&amp;form=6&amp;db=m&amp;Dopt=b"><i>Lancet</i>
    344:1383&#150;1389, 1994</a></font></p>
    </div><div><a name="8"><p><font face="Times New Roman" size="3">8.</a> Shepherd J, Cobbe
    SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of
    coronary heart disease with pravastatin in men with hypercholesterolemia. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7566020&amp;form=6&amp;db=m&amp;Dopt=b"><i>N
    Engl J Med</i> 333:1301&#150;1307, 1995</a></font></p>
    </div><div><a name="9"><p><font face="Times New Roman" size="3">9.</a> Sacks FM, Pfeffer
    MA, Lemuel A: The effect of pravastatin on coronary events after myocardial infarction in
    patients with average cholesterol levels. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8801446&amp;form=6&amp;db=m&amp;Dopt=b"><i>N
    Engl J Med</i> 335:1001&#150;1009, 1996</a></font></p>
    </div><div><a name="10"><p><font face="Times New Roman" size="3">10.</a> The Long-Term
    Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of
    cardiovascular events and death with pravastatin in patients with coronary heart disease
    and a broad range of initial cholesterol levels. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9841303&amp;form=6&amp;db=m&amp;Dopt=b"><i>N
    Engl J Med</i> 339:1349&#150;1357, 1998</a></font></p>
    </div><div><a name="11"><p><font face="Times New Roman" size="3">11.</a> Downs JR,
    Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W,
    Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women
    with average cholesterol levels. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9613910&amp;form=6&amp;db=m&amp;Dopt=b"><i>JAMA</i>
    279:1615&#150;1622, 1998</a></font></p>
    </div><div><a name="12"><p><font face="Times New Roman" size="3">12.</a> Pyorala K,
    Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with
    simvastatin improves prognosis of diabetic patients with coronary heart disease. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9096989&amp;form=6&amp;db=m&amp;Dopt=b"><i>Diabetes
    Care</i> 20:614&#150;620, 1997</a></font></p>
    </div><div><a name="13"><p><font face="Times New Roman" size="3">13.</a> Grunler J,
    Ericsson J, Dallner G: Branch-point reactions in the biosynthesis of cholesterol,
    dolichol, ubiquinone and prenylated proteins. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8199197&amp;form=6&amp;db=m&amp;Dopt=b"><i>Biochim
    Biophys Acta</i> 1212:259&#150;277, 1994</a></font></p>
    </div><div><a name="14"><p><font face="Times New Roman" size="3">14.</a> Goldstein JL,
    Brown MS: Regulation of the mevalonate pathway. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1967820&amp;form=6&amp;db=m&amp;Dopt=b"><i>Nature</i>
    343:425&#150;430, 1990</a></font></p>
    </div><div><a name="15"><p><font face="Times New Roman" size="3">15.</a> Bernini F, Didoni
    G, Bonfadini G, Bellosta S, Fumagalli R: Requirement for mevalonate in acetylated LDL
    induction of cholesterol esterification in macrophages. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8141843&amp;form=6&amp;db=m&amp;Dopt=b"><i>Atherosclerosis
    </i>104:19&#150;26, 1993</a></font></p>
    </div><div><a name="16"><p><font face="Times New Roman" size="3">16.</a> Corsini A,
    Mazzotti M, Raiteri M, Soma MR, Gabbiani G, Fumagalli R, Paoletti R: Relationship between
    mevalonate pathway and arterial myocyte proliferation: <i>in vitro</i> studies with
    inhibitors of HMG-CoA reductase. <i>Atherosclerosis</i> 101:117&#150;125, 1993</font></p>
    </div><div><a name="17"><p><font face="Times New Roman" size="3">17.</a> Ross R:
    Atherosclerosis: an inflammatory disease. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9887164&amp;form=6&amp;db=m&amp;Dopt=b"><i>N
    Engl J Med</i> 340:115&#150;126, 1999</a></font></p>
    </div><div><a name="18"><p><font face="Times New Roman" size="3">18.</a> Wissler RW:
    Update on the pathogenesis of atherosclerosis. <i>Am J Med</i> 91 (Suppl.
    1B):1B-3S&#150;1B-9S, 1991</font></p>
    </div><div><a name="19"><p><font face="Times New Roman" size="3">19.</a> Schwartz CJ,
    Valente AJ, Sprague EA: A modern view of atherogenesis. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8434561&amp;form=6&amp;db=m&amp;Dopt=b"><i>Am
    J Cardiol</i> 71:9B&#150;14B, 1993</a></font></p>
    </div><div><a name="20"><p><font face="Times New Roman" size="3">20.</a> Corsini A,
    Raiteri M, Soma MR, Bernini F, Fumagalli R, Paoletti R: Pathogenesis of atherosclerosis
    and the role of drug intervention: focus on HMG-CoA reductase inhibitors. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7604791&amp;form=6&amp;db=m&amp;Dopt=b"><i>Am
    J Cardiol</i> 76:21A&#150;28A, 1995</a></font></p>
    </div><div><a name="21"><p><font face="Times New Roman" size="3">21.</a> Ross R: The
    smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic
    fibers. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4327464&amp;form=6&amp;db=m&amp;Dopt=b"><i>J
    Cell Biol</i> 50:172&#150;186, 1971</a></font></p>
    </div><div><a name="22"><p><font face="Times New Roman" size="3">22.</a> Bellosta S, Via
    D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, Bernini F: HMG-CoA reductase inhibitors
    reduce MMP-9 secretion by macrophages. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9812903&amp;form=6&amp;db=m&amp;Dopt=b"><i>Arterioscler
    Thromb Vasc Biol </i>18:1671&#150;1678, 1998</a></font></p>
    </div><div><a name="23"><p><font face="Times New Roman" size="3">23.</a> Bernini F,
    Scurati N, Bonfadini G, Fumagalli R: HMG-CoA reductase inhibitors reduce acetyl LDL
    endocytosis in mouse peritoneal macrophages. <i>Arterioscler Thromb Vasc Biol</i>
    15:1352&#150;1358, 1996</font></p>
    </div><div><a name="24"><p><font face="Times New Roman" size="3">24.</a> Corsini A,
    Arnaboldi L, Raiteri M, Quarato P, Faggiotto A, Paoletti R, Fumagalli R: Effect of the new
    HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and
    cholesterol synthesis in arterial myocytes. <i>Pharmacol Res</i> 33:56&#150;62, 1996</font></p>
    </div><div><a name="25"><p><font face="Times New Roman" size="3">25.</a> Raiteri M,
    Arnaboldi L, McGeady P, Gelb MH, Verri D, Tagliabue C, Quarato P, Ferraboschi P,
    Santaniello E, Paoletti R, Fumagalli R, Corsini A: Pharmacological control of the
    mevalonate pathway: effect on arterial smooth muscle cell proliferation.<a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9190847&amp;form=6&amp;db=m&amp;Dopt=b"><i>
    J Pharmacol Exp Ther</i> 281:1144&#150;1153, 1997</a></font></p>
    </div><div><a name="26"><p><font face="Times New Roman" size="3">26.</a> Scott W:
    Hydrophilicity and the differential pharmacology of pravastatin. In <i>Lipid Management:
    Pravastatin and the Differential Pharmacology of HMG-CoA Reductase Inhibitors. </i>Wood C,
    Ed. London, London Round Table Series, no. 16, Royal Society of Medicine Service, 1989, p.
    17&#150;25</font></p>
    </div><div><a name="27"><p><font face="Times New Roman" size="3">27.</a> Komai T,
    Shigehara E, Tokui T: Carrier-mediated uptake of pravastatin by rat hepatocytes in primary
    culture. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1540221&amp;form=6&amp;db=m&amp;Dopt=b"><i>Biochem
    Pharmacol</i> 43:667&#150;670, 1992</a></font></p>
    </div><div><a name="28"><p><font face="Times New Roman" size="3">28.</a> Dain JG, Fu E,
    Gorski J, Nicoletti J, Scallen TJ: Biotransformation of fluvastatin sodium in humans. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8104114&amp;form=6&amp;db=m&amp;Dopt=b"><i>Drug
    Metab Dispos</i> 21:567&#150;572, 1993</a></font></p>
    </div><div><a name="29"><p><font face="Times New Roman" size="3">29.</a> Tse FLS, Jaffe
    JM, Troendle A: Pharmacokinetics of fluvastatin after single and multiple doses of normal
    volunteers. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1640002&amp;form=6&amp;db=m&amp;Dopt=b"><i>J
    Clin Pharmacol</i> 32:630&#150;638, 1992</a></font></p>
    </div><div><a name="30"><p><font face="Times New Roman" size="3">30.</a> Corsini A,
    Pazzucconi F, Pfister P, Paoletti R, Sirtori CR: Inhibitor of proliferation of arterial
    smooth muscle cells by fluvastatin (Letter). <i>Lancet</i> 348:1584, 1996</font></p>
    </div><div><a name="31"><p><font face="Times New Roman" size="3">31.</a> Falk E, Shah PK,
    Fuster V: Coronary plaque disruption. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7634481&amp;form=6&amp;db=m&amp;Dopt=b"><i>Circulation</i>
    92:657&#150;671, 1995</a></font></p>
    </div><div><a name="32"><p><font face="Times New Roman" size="3">32.</a> Davies MJ,
    Richardson PD, Woolf N, Katz DR, Mann J: Risk of thrombosis in human atherosclerotic
    plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8518056&amp;form=6&amp;db=m&amp;Dopt=b"><i>Br
    Heart J</i> 69:377&#150;381, 1993</a></font></p>
    </div><div><a name="33"><p><font face="Times New Roman" size="3">33.</a> Fernandez-Ortiz
    A, Badimon J, Falk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L:
    Characterization of the relative thrombogenicity of atherosclerotic plaque components:
    implications for consequences of plaque rupture. <i>Am J Coll Cardiol</i>
    23:1562&#150;1569, 1994</font></p>
    </div><div><a name="34"><p><font face="Times New Roman" size="3">34.</a> Dollery CM,
    McEwan JR, Henney AM: Matrix metalloproteinases and cardiovascular disease. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7554139&amp;form=6&amp;db=m&amp;Dopt=b"><i>Circ
    Res</i> 77:863&#150;868, 1995</a></font></p>
    </div><div><a name="35"><p><font face="Times New Roman" size="3">35.</a> Bellosta S,
    Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L, Fumagalli R, Paoletti R, Corsini
    A: Direct vascular effects of HMG-CoA reductase inhibitors. <i>Atherosclerosis </i>137
    (Suppl.):S101&#150;S109, 1998</font></p>
    </div><div><a name="36"><p><font face="Times New Roman" size="3">36.</a> Corsini A,
    Pazzucconi F, Arnaboldi L, Pfister P, Fumagalli R, Paoletti R, Sirtori CR: Direct effects
    of statins on the vascular wall. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9593078&amp;form=6&amp;db=m&amp;Dopt=b"><i>J
    Cardiovasc Pharmacol</i> 31:773&#150;778, 1998</a></font></p>
    </div><div><a name="37"><p><font face="Times New Roman" size="3">37.</a> Serruys PW, Foley
    DP, Jackson G, Bonnier H, Macaya C, Vrolix M, Branzi A, Shepherd J, Suryapranaia H, de
    Feyter PJ, Melkert R, van Es GA, Pfister PJ, for the FLARE Study Group: A randomized
    placebo-controlled trial of fluvastatin for prevention of restenosis after successful
    coronary balloon angioplasty. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10075142&amp;form=6&amp;db=m&amp;Dopt=b"><i>Eur
    Heart J </i>20:58&#150;69, 1999</a></font></p>
    </div><div><a name="38"><p><font face="Times New Roman" size="3">38.</a> Weintraub WS,
    Boccuzzi SJ, Klein JL, on behalf of the Lovastatin Restenosis Trail Study Group: Lack of
    effect of lovastatin on restenosis after coronary angioplasty. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7935702&amp;form=6&amp;db=m&amp;Dopt=b"><i>N
    Engl J Med</i> 331:1331&#150;1337, 1994</a></font></p>
    </div><div><a name="39"><p><font face="Times New Roman" size="3">39.</a> Bertrand ME,
    McFadden EP, Fruchart JC, for the PREDICT Trial Investigators: Effects of pravastatin on
    angiographic restenosis after coronary balloon angioplasty. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9316510&amp;form=6&amp;db=m&amp;Dopt=b"><i>J
    Am Coll Cardiol</i> 30:863&#150;869, 1997</a></font></p>
    </div><div><a name="40"><p><font face="Times New Roman" size="3">40.</a> Rosenson RS,
    Tangney C: Antiatherothrombotic properties of statins. <i>J Am Med Assoc </i>279:1643&#150;1650,
    1998</font></p>
    </div><div><a name="41"><p><font face="Times New Roman" size="3">41.</a> Colli S, Eligini
    S, Lalli M, Camera M, Paletti R, Tremoli E: Vastatins inhibit tissue factor in cultured
    human macrophages: a novel mechanism of protection against atherothrombosis. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9081680&amp;form=6&amp;db=m&amp;Dopt=b"><i>Arterioscler
    Thromb Vasc Biol</i> 17:265&#150;272, 1997</a></font></p>
    </div><div><a name="42"><p><font face="Times New Roman" size="3">42.</a> Essig M, Nguyen
    G, Pri D, Escoubet B, Sraer JD, Friedlander G: 3-Hydroxy-3-methylglutaryl coenzyme A
    reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9758637&amp;form=6&amp;db=m&amp;Dopt=b"><i>Circ
    Res</i> 83:683&#150;690, 1998</a></font></p>
    </div><div><a name="43"><p><font face="Times New Roman" size="3">43.</a> Hussein O,
    Schlezinger S, Rosenblat M, Kheidar S, Aviram M: Reduced susceptibility of low density
    lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the
    hypocholesterolemic effect of the drug and its binding to the LDL. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9051193&amp;form=6&amp;db=m&amp;Dopt=b"><i>Atherosclerosis
    </i>128:11&#150;18, 1997</a></font></p>
    </div><div><a name="44"><p><font face="Times New Roman" size="3">44.</a> Sakai M, Kobori
    S, Matsumura T, Biwa T, Sato Y, Takemura T, Hakamata H, Horiuchi S, Shichiri M: HMG-CoA
    reductase inhibitors suppress macrophage growth induced by oxidized low density
    lipoprotein.<a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9258407&amp;form=6&amp;db=m&amp;Dopt=b"><i>
    Atherosclerosis</i> 133:51&#150;59, 1997</a></font></p>
    </div><div><a name="45"><p><font face="Times New Roman" size="3">45.</a> Giroux LM,
    Davignon J, Naruzewicz M: Simvastatin inhibits the oxidation of low-density lipoproteins
    by activated human monocyte-derived macrophages. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8380338&amp;form=6&amp;db=m&amp;Dopt=b"><i>Biochim
    Biophys Acta</i> 1165:335&#150;338, 1993</a></font></p>
    </div><div><a name="46"><p><font face="Times New Roman" size="3">46.</a> Kobashigawa JA,
    Katznelson S, Hillel L, Johnson JA, Yeatman L, Wang XM: Effect of pravastatin on outcomes
    after cardiac transplantation. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7637722&amp;form=6&amp;db=m&amp;Dopt=b"><i>N
    Engl J Med</i> 333:621&#150;627, 1995</a></font></p>
    </div><div><a name="47"><p><font face="Times New Roman" size="3">47.</a> Umetani N,
    Kanayama Y, Okamura M, Negoro N, Takeda T: Lovastatin inhibits gene expression of type-I
    scavenger receptor in THP-1 human macrophages. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8908154&amp;form=6&amp;db=m&amp;Dopt=b"><i>Biochim
    Biophys Acta</i> 1303:199&#150;206, 1996</a></font></p>
    </div><div><a name="48"><p><font face="Times New Roman" size="3">48.</a> La Ville A, Moshy
    R, Turner PR, Miller NE, Lewis B: Inhibition of cholesterol synthesis reduces
    low-density-lipoprotein apoprotein B production without decreasing very-low-density
    lipoprotein apoprotein B synthesis in rabbits. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6562889&amp;form=6&amp;db=m&amp;Dopt=b"><i>Biochem
    J</i> 219:321&#150;323, 1984</a></font></p>
    </div><div><a name="49"><p><font face="Times New Roman" size="3">49.</a> Masaaki K, Kurose
    I, Russell J, Granger DN: Effect of fluvastatin on leukocyte-endothelial cell adhesion in
    hypercholesterolemic rats. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9301630&amp;form=6&amp;db=m&amp;Dopt=b"><i>Arterioscler
    Thromb Vasc Biol</i> 17:1521&#150;1526, 1997</a></font></p>
    </div><div><a name="50"><p><font face="Times New Roman" size="3">50.</a> Endres M, Laufs
    U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK: Stroke protection by
    3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric
    oxide synthase. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9671773&amp;form=6&amp;db=m&amp;Dopt=b"><i>Proc
    Natl Acad Sci U S A</i> 95:8880&#150;8885, 1998</a></font></p>
    </div><div><a name="51"><p><font face="Times New Roman" size="3">51.</a> Hernandez-Perera
    O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S:
    Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and
    simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in
    vascular endothelial cells. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9637705&amp;form=6&amp;db=m&amp;Dopt=b"><i>J
    Clin Invest</i> 101:2711&#150;2719, 1998</a></font></p>
    </div><div><a name="52"><p><font face="Times New Roman" size="3">52.</a> Bandoh T, Mitani
    H, Niihashi M, Bandoh T, Mitani H, Niihashi M, Kusumi Y, Ishikawa J, Kimura M, Totsuka T,
    Sakurai I, Hayashi S: Inhibitory effect of fluvastatin at doses insufficient to lower
    serum lipids on the catheter-induced thickening of intima in rabbit femoral artery. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8960862&amp;form=6&amp;db=m&amp;Dopt=b"><i>Eur
    J Pharmacol</i> 315:37&#150;42, 1996</a></font></p>
    </div><div><a name="53"><p><font face="Times New Roman" size="3">53.</a> Igarashi M,
    Takeda Y, Mori S, Ishibashi N, Komatsu E, Takahashi K, Fuse T, Yamamura M, Kubo K,
    Sugiyama Y, Saito Y: Suppression of neointimal thickening by a newly developed HMG-CoA
    reductase inhibitor, BAYW6228 and its inhibitory effect on vascular smooth muscle cell
    growth. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9134232&amp;form=6&amp;db=m&amp;Dopt=b"><i>Br
    J Pharmacol</i> 120:1172&#150;1178, 1997</a></font></p>
    </div><div><a name="54"><p><font face="Times New Roman" size="3">54.</a> Soma MR, Donetti
    E, Parolini C, Mazzini G, Ferrari C, Fumagalli R, Paoletti R: HMG-CoA reductase
    inhibitors: <i>in vivo</i> effects on carotid intimal thickening in normocholesterolemic
    rabbits. <i>Arterioscler Thromb Vasc Biol</i> 13:571&#150;578, 1993</font></p>
    </div><div><a name="55"><p><font face="Times New Roman" size="3">55.</a> Soma MR, Parolini
    C, Donetti E, Fumagalli R, Paoletti R: Inhibition of isoprenoids biosynthesis and arterial
    smooth muscle cell proliferation. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8907210&amp;form=6&amp;db=m&amp;Dopt=b"><i>J
    Cardiovasc Pharmacol</i> 25:S20&#150;S24, 1995</a></font></p>
    </div><div><a name="56"><p><font face="Times New Roman" size="3">56.</a> Bocan TMA, Mazur
    MJ, Mueller SB, Brown EQ, Sliskovic DR, O'Brien PM, Creswell MW, Lee H, Uhlendorf PD, Roth
    BD: Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A
    reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7840808&amp;form=6&amp;db=m&amp;Dopt=b"><i>Atherosclerosis</i>
    111:127&#150;142, 1994</a></font></p>
    </div><div><a name="57"><p><font face="Times New Roman" size="3">57.</a> Gellman J,
    Ezekowitz MD, Sarembock IJ, Azrin MA, Nochomowitz LE, Lerner E, Haudenschild CC: Effect of
    lovastatin on intimal hyperplasia after balloon angioplasty: a study in an atherosclerotic
    hypercholesterolemic rabbit. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1824771&amp;form=6&amp;db=m&amp;Dopt=b"><i>J
    Am Coll Cardiol</i> 17:251&#150;259, 1991</a></font></p>
    </div><div><a name="58"><p><font face="Times New Roman" size="3">58.</a> Zhu BQ, Sievers
    RE, Sun YP, Isenberg WM, Parmley WW: Effect of lovastatin on suppression and regression of
    atherosclerosis in lipid-fed rabbits. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1376794&amp;form=6&amp;db=m&amp;Dopt=b"><i>J
    Cardiovasc Pharmacol</i> 19:246&#150;255, 1992</a></font></p>
    </div><div><a name="59"><p><font face="Times New Roman" size="3">59.</a> Williams JK,
    Sukhova GK, Herrington DM, Libby P: Pravastatin has cholesterol-lowering independent
    effects on the artery wall of atherosclerotic monkeys. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9502654&amp;form=6&amp;db=m&amp;Dopt=b"><i>J
    Am Coll Cardiol</i> 31:684&#150;691, 1998</a></font></p>
    </div><div><a name="60"><p><font face="Times New Roman" size="3">60.</a> O'Driscoll G,
    Green D, Taylor RR: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves
    endothelial function within 1 month. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9054840&amp;form=6&amp;db=m&amp;Dopt=b"><i>Circulation</i>
    95:1126&#150;1131, 1997</a></font></p>
    </div><div><a name="61"><p><font face="Times New Roman" size="3">61.</a> Buchwald H, Varco
    RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smik RD
    Jr: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart
    disease in patients with hypercholesterolemia: report of the Program on the Surgical
    Control of the Hyperlipidemias (POSCH). <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2205799&amp;form=6&amp;db=m&amp;Dopt=b"><i>N
    Engl J Med</i> 323:946&#150;955, 1990</a></font></p>
    </div><div><a name="62"><p><font face="Times New Roman" size="3">62.</a> Herd JA,
    Ballantyne CM, Farmer JA, Ferguson JJ III, Jones PH, West MS, Gould KL, Gotto AM Jr:
    Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate
    cholesterol elevations (Lipoproteins and Coronary Atherosclerosis Study [LCAS]). <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9264419&amp;form=6&amp;db=m&amp;Dopt=b"><i>Am
    J Cardiol</i> 80:278&#150;286, 1997</a></font></p>
    </div><div><a name="63"><p><font face="Times New Roman" size="3">63.</a> Bierman EL:
    Atherogenesis in diabetes. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1591228&amp;form=6&amp;db=m&amp;Dopt=b"><i>Arterioscler
    Thromb</i> 12:647&#150;656, 1992</a></font></p>
    </div><div><a name="64"><p><font face="Times New Roman" size="3">64.</a> Arbeeny CM,
    Berquist KE: The effect of pravastatin on serum cholesterol levels in hypercholesterolemic
    diabetic rabbits. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1902119&amp;form=6&amp;db=m&amp;Dopt=b"><i>Biochim
    Biophys Acta</i> 1096:238&#150;244, 1991</a></font></p>
    </div><div><a name="65"><p><font face="Times New Roman" size="3">65.</a> Maeda E, Yoshino
    G, Matsushita M, Nagata K, Morita M, Mutata Y, Naka Y, Kazumi T: Effect of a
    3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on triglyceride kinetics in
    chronically streptozotocin-diabetic rats. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8446048&amp;form=6&amp;db=m&amp;Dopt=b"><i>Metabolism</i>
    42:52&#150;57, 1993</a></font></p>
    </div><div CLASS="Reprint-first"><hr>
    <p><font face="Times New Roman" size="3">From the Institute of Pharmacological Sciences
    (S.B., N.F., L.A., R.P., A.C.), University of Milan, Milan; and the Institute of
    Pharmacology and Pharmacognosy (F.B.), University of Parma, Parma, Italy.</font></p>
    </div><div CLASS="Reprint"><p><font face="Times New Roman" size="3">Address correspondence
    and reprint requests to Alberto Corsini, PhD, Institute of Pharmacological Sciences,
    University of Milan, via Balzaretti 9, 20133 Milan, Italy. E-mail: <a href="mailto:alberto.corsini@unimi.it">alberto.corsini@unimi.it</a>. </font></p>
    </div><div CLASS="Reprint"><p><font face="Times New Roman" size="3">Received for
    publication 9 July 1999 and accepted in revised form 19 November 1999.</font></p>
    </div><div CLASS="Reprint"><p><font face="Times New Roman" size="3"><strong>Abbreviations</strong>:
    4S, Scandinavian Simvastatin Survival Study; CARE, Cholesterol and Recurrent Events; CHD,
    coronary heart disease; F-OH, farnesol; GG-OH, geranylgeraniol; HMG,
    3-hydroxy-3-methylglutaryl; LIPID, Long-Term Intervention with Pravastatin in Ischemic
    Disease; MEM, minimum essential medium; MMP, metalloproteinase; MVA, mevalonic acid; SMC,
    smooth muscle cell.</font></p>
    <div CLASS="Reprint"><p><font face="Times New Roman" size="3">A table elsewhere in this
    issue shows conventional and Syst�me International (SI) units and conversion factors for
    many substances.</font></p>
    </div><div CLASS="Reprint"><p><font face="Times New Roman" size="3">This article is based
    on a presentation at a symposium. The symposium and the publication of this article were
    made possible by an unrestricted educational grant from Aventis Pharma.</font></p>
    </div></div><hr>
    <p align="center"><a href="../../../../CareSup2April00.asp"><font size="3"><strong>Return
    to Supplement Contents</strong></font></a></p>
    <p align="center"><font size="1"><b>Copyright � 2000 American Diabetes Association</b> <br>
    <b>Last updated: 3/00<br>
    For ADA Related Issues contact</b> <a href="mailto:%22CustomerService@diabetes.org%22">CustomerService@diabetes.org</a></font></p>
    <p align="center"><font size="1"><b>For Technical Issues contact</b> <a href="mailto:%22webmaster@diabetes.org%22">webmaster@diabetes.org</a></font></td>
  </tr>
</table>
</div>
</body>
</html>
